US4496558A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions and methods for producing alpha antagonism
Assignee: SmithKline Beecham Corp
•
Filing: 1983-01-26
•
Granted: 1985-01-29
•
Expires: 2003-01-26
Abstract
Abstract Pharmaceutical compositions and methods for producing alpha 2 antagonism utilize, as active ingredients, 6-halo-N-substituted 2,3,4,5-tetrahydro-1H-3-benzazepines. These compositions are particularly useful for lowering intraocular pressure and for the treatment of abnormal cardiovascular conditions such as, for example, congestive heart failure, angina pectoris and thrombosis. The compositions and compounds of this invention, also, produce a reduction in blood pressure in hypertensive subjects and are, therefore, useful as antihypertensive agents.
Inventors
- 👤 Robert M. DeMarinis
- 👤 Jacob P. Hieble
- 👤 William D. Matthews
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 22:34
CPC Classifications
C; C07; C07D; C07D223/00; C07D223/14; C07D223/16
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
47 words
A pharmaceutical composition for product alpha 2 antagonism comprising a pharmaceutically acceptable carrier and a nontoxic, effective amount to produce said antagonism of a 3-benzazepine compound of the formula: ##STR3## in which: R is allyl; and X is halogen; or a pharmaceutically acceptable, acid addition salt thereof.
Claim 2
Dependent Claim
47 words
A pharmaceutical composition for product alpha 2 antagonism comprising a pharmaceutically acceptable carrier and a nontoxic, effective amount to produce said antagonism of a 3-benzazepine compound of the formula: ##STR3## in which: R is allyl; and X is halogen; or a pharmaceutically acceptable, acid addition salt thereof.
Claim 3
Dependent Claim
25 words
A pharmaceutical composition for producing antihypertensive activity comprising a pharmaceutically acceptable carrier and a nontoxic, antihypertensive effective amount of a 3-benzazepine compound of claim 1.
Claim 4
Dependent Claim
11 words
The pharmaceutical composition of claim 2 in which X is chloro.
Claim 5
Dependent Claim
17 words
The composition of claim 3 in which the compound is in the form of its hydrochloride salt.
Claim 6
Dependent Claim
11 words
The pharmaceutical composition of claim 1 in which X is chloro.
Claim 7
Dependent Claim
17 words
The composition of claim 5 in which the 3-benzazepine is in the form of its hydrochloride salt.
Claim 8
Independent Claim
54 words
A method of producing alpha 2 antagonist activity in a subject in need of such activity comprising administering to said subject a nontoxic amount sufficient to produce said activity of a 3-benzazepine compound of the formula: ##STR4## in which: R is allyl; and X is halogen; or a pharmaceutically acceptable, acid addition salt thereof.
Claim 9
Independent Claim
54 words
A method of producing alpha 2 antagonist activity in a subject in need of such activity comprising administering to said subject a nontoxic amount sufficient to produce said activity of a 3-benzazepine compound of the formula: ##STR4## in which: R is allyl; and X is halogen; or a pharmaceutically acceptable, acid addition salt thereof.
Claim 10
Dependent Claim
10 words
The method of claim 7 in which X is chloro.
Claim 11
Dependent Claim
17 words
The method of claim 8 in which the compound is in the form of its hydrochloride salt.
Claim 12
Dependent Claim
30 words
A method of producing antihypertensive activity in a hypertensive subject comprising administering to said subject a nontoxic amount sufficient to produce said activity of a 3-benzazepine compound of claim 7.
Claim 13
Dependent Claim
38 words
The method of claim 10 in which said compound is administered orally or parenterally in a nontoxic, antihypertensive amount selected from the range of about 50 mg. to 250 mg. administered from about 2 to 4 times daily.
Claim 14
Dependent Claim
10 words
The method of claim 10 in which X is chloro.
Claim 15
Dependent Claim
17 words
The method of claim 12 in which the compound is in the form of its hydrochloride salt.
References Cited (Backward Citations)
US2520264A
Cited
GB1268243A
Cited
US4233217A
Cited
US3716639A
Cited
US3752892A
Cited
US3795683A
Cited
US3906006A
Cited
US4065473A
Cited
US4210749A
Cited
US4265890A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-01-29 | 1988-07-30 | 1989-01-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-01-29 | 1992-07-30 | 1993-01-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-01-29 | 1996-07-30 | 1997-01-29 | $7700.00 | Window Closed / Lapsed |